Efficacy of biologics in atopic dermatitis
The DOI matches its Crossref record; 172 of the 172 references it cites were found in a registry or an index.
Abstract
Introduction: Atopic dermatitis (AD) is a heterogeneous disease. Recent advancements in understanding AD pathogenesis resulted in the exponential expansion of its therapeutic pipeline, particularly following the success and FDA-approval of dupilumab. Different phenotypes of AD by age and ethnicity have also recently been described and clinical studies of emerging treatments will further clarify the role of each cytokine pathway in AD.Areas covered: We review the impressive repertoire of biologics for treatment of moderate-to-severe AD, including those targeting Th2, Th22, Th17/IL-23 and IgE. We highlight the scientific rationale behind each approach and provide a discussion of the most recent clinical efficacy and safety data.Expert opinion: AD is a complex disease and recent research has identified numerous endotypes, reinforcing the rationale for developing targeted therapeutics to antagonize these factors. Dupilumab has revolutionized AD treatment and its mechanistic studies also offer crucial insight into AD pathogenesis. Nevertheless, this biologic does not work for everyone, highlighting the need for a more precise approach to address the unique immune fingerprints of each AD subset. Ultimately targeted therapeutics will complement our understanding of the AD molecular map and help push AD management into an era of personalized medicine.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Dupilumab and tralokinumab are examples of targeted biologic therapies that specifically address a distinct immune pathway and its cytokines or receptors16,”
From Atopic dermatitis: an expanding therapeutic pipeline for a complex disease (2022) · cites this paper as [16]
Citations
Cites
Diagnostic features of atopic dermatitis
Hanifin, J. M., & Rajka, G. (1980) · Acta Dermato-Venereologica · doi:10.2340/00015555924447 · Cited by 5,086
Williams, H. C., Leung, D. Y. M., Thestrup‐Pedersen, K., & David, T. J. (2000) · Cited by 4,599
Schmitz, J., Owyang, A., Oldham, E., Song, Y., Murphy, E., McClanahan, T. K., Zurawski, G., Moshrefi, M., Qin, J., Li, X., et al. (2005) · Immunity · doi:10.1016/j.immuni.2005.09.015 · Cited by 3,710
Human epithelial cells trigger dendritic cell–mediated allergic inflammation by producing TSLP
Soumelis, V., Reche, P. A., Kanzler, H., Yuan, W., Edward, G., Homey, B., Gilliet, M., Ho, S., Antonenko, S., Lauerma, A., et al. (2002) · Nature Immunology · doi:10.1038/ni805 · Cited by 2,183 · cited 1×
“Finally, TSLP protein is found to be overexpressed in the keratinocytes in patients with acute or chronic AD [93].”
BackgroundTwo Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis
Simpson, E. L., Bieber, T., Guttman-Yassky, E., Beck, L. A., Blauvelt, A., Cork, M. J., Silverberg, J. I., Deleuran, M., Kataoka, Y., Lacour, J.-P., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1610020 · Cited by 2,110 · cited 2×
“In SOLO1 and SOLO2, adults with moderate-to-severe AD inadequately controlled on topical therapies were randomized to subcutaneous dupilumab 300 mg weekly, 300 mg every other week alternating with placebo (q2w), or placebo weekly (qw) [44].”
BackgroundSelf-citationSecukinumab in plaque psoriasis—results of two phase 3 trials
Langley, R. G., Elewski, B. E., Lebwohl, M., Reich, K., Griffiths, C. E. M., Papp, K., Puig, L., Nakagawa, H., Spelman, L., Sigurgeirsson, B., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1314258 · Cited by 1,997 · cited 1×
“IL-17A and IL-17F, have both demonstrated robust data for psoriasis [163,164].”
BackgroundWeidinger, S., & Novak, N. (2016) · The Lancet · doi:10.1016/s0140-6736(15)00149-x · Cited by 1,908
Leonardi, C. L., Kimball, A. B., Papp, K. A., Yeilding, N., Guzzo, C., Wang, Y., Li, S., Dooley, L. T., & Gordon, K. B. (2008) · The Lancet · doi:10.1016/s0140-6736(08)60725-4 · Cited by 1,874
Interleukin-22, a TH17 cytokine, mediates IL-23-induced dermal inflammation and acanthosis
Zheng, Y., Danilenko, D. M., Valdez, P., Kasman, I., Eastham-Anderson, J., Wu, J., & Ouyang, W. (2007) · Nature · doi:10.1038/nature05505 · Cited by 1,862
Self-citationDupilumab Treatment in Adults with Moderate-to-Severe Atopic Dermatitis
Beck, L. A., Thaçi, D., Hamilton, J. D., Graham, N. M., Bieber, T., Rocklin, R., Ming, J. E., Ren, H., Kao, R., Simpson, E., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1314768 · Cited by 1,421
Self-citation
Research works printed but not linked: 6
- TC SR C, 2018, J Invest Dermatol, 138(5, Suppleme
- He H, 2020, Ann Allergy Asthma Immunol, 124
- Gooderham MJ, 2020, JAMA dermatology, 155
- Eyerich S, 2009, J Clin Invest, 119, 3573
- Weber A, 2010, Sci Signal, 3, cm1
- 10.1038/nri2691 · DOI · Paper page
Cited by
Molecular Mechanisms of Atopic Dermatitis Pathogenesis
Sroka-Tomaszewska, J., & Trzeciak, M. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22084130 · Cited by 577
Atopic dermatitis: an expanding therapeutic pipeline for a complex disease
Bieber, T. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00266-6 · Cited by 623
Endophenotypic Variations of Atopic Dermatitis by Age, Race, and Ethnicity
Nomura, T., Wu, J., Kabashima, K., & Guttman-Yassky, E. (2020) · The Journal of Allergy and Clinical Immunology: In Practice · doi:10.1016/j.jaip.2020.02.022 · Cited by 128
Self-citationMeng, J., Li, Y., Fischer, M. J. M., Steinhoff, M. S., Chen, W., & Wang, J. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.696784 · Cited by 117
Pavel, A. B., Renert‐Yuval, Y., Wu, J., Del Duca, E., Diaz, A., Lefferdink, R., Fang, M. M., Canter, T., Rangel, S. M., Zhang, N., et al. (2021) · Allergy · doi:10.1111/all.14490 · Cited by 112
Self-citation
Metadata
- Authors
- Wu, J., & Guttman-Yassky, E.
- Affiliations
- SUNY Downstate Health Sciences University (US)
- Department of Dermatology, Laboratory of Inflammatory Skin Diseases, Icahn School of Medicine at Mount Sinai, New York, USA
- Venue
- Expert Opinion on Biological Therapy
- Publisher
- Informa UK Limited
- Published
- 2020-02-03
- Volume
- 20
- Issue
- 5
- Pages
- 525-538
- ISSN
- 1471-2598 (ISSN-L)
- 1744-7682
- OpenAlex
- W3004019018
- Cited by
- 46
- References
- 172
- Citations by year
- 2026: 3 · 2025: 5 · 2024: 3 · 2023: 2 · 2022: 7 · 2021: 17 · 2020: 9
- FWCI
- 1.46
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Expert Opinion on Biological Therapy (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Dermatology › Dermatology and Skin Diseases
- Life Sciences › Immunology and Microbiology › Immunology › Psoriasis: Treatment and Pathogenesis
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Asthma and respiratory diseases
- Keywords
- atopic dermatitis, biologic therapy, dupilumab, Th2 cytokines, IgE, disease endotypes, personalized medicine, moderate-to-severe atopic dermatitis, treatment efficacy and safety
- MeSH terms
- Interleukin-22, Antibodies, Monoclonal, Biological Products, Dermatitis, Atopic, Humans, Immunoglobulin E, Interleukins, Th2 Cells, Interleukin-17, Interleukin-23, Th17 Cells
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Efficacy of biologics in atopic dermatitis. https://app.cochat.ai/papers/10.1080/14712598.2020.1722998
- The paper
- Wu, J., & Guttman-Yassky, E. (2020). Efficacy of biologics in atopic dermatitis. Expert Opinion on Biological Therapy. https://doi.org/10.1080/14712598.2020.1722998
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.